nach oben

Journal of Cardiovascular Translational Research

Erschienen in:

31.08.2018 | Review

Noncoding RNAs in Cardiac Hypertrophy

verfasst von: Yongqin Li, Yajun Liang, Yujiao Zhu, Yuhui Zhang, Yihua Bei

Erschienen in: Journal of Cardiovascular Translational Research | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Cardiac hypertrophy is classified as pathological and physiological hypertrophy. Pathological hypertrophy typically precedes the onset of heart failure, one of the largest contributors to disease burden and deaths worldwide. In contrast, physiological hypertrophy is an adaptive response and protects against adverse cardiac remodeling. Noncoding RNAs (ncRNAs) have drawn significant attention over the last couple of decades, and their dysregulation is increasingly being linked to cardiac hypertrophy and cardiovascular diseases. In this review, we will summarize the profiling, function, and molecular mechanism of microRNAs, long noncoding RNAs, and circular RNAs in pathological cardiac hypertrophy. Additionally, we also review microRNAs responsible for physiological hypertrophy. With better understanding of ncRNAs in cardiac hypertrophy, manipulation of the important ncRNAs will offer exciting avenues for the prevention and therapy of heart failure.

Iismaa, S. E., & Graham, R. M. (2003). Dissecting cardiac hypertrophy and signaling pathways: evidence for an interaction between multifunctional g proteins and prostanoids. Circulation Research, 92(10), 1059–1061.PubMed

Shimizu, I., & Minamino, T. (2016). Physiological and pathological cardiac hypertrophy. Journal of Molecular and Cellular Cardiology, 97, 245–262.PubMed

Frey, N., & Olson, E. N. (2003). Cardiac hypertrophy: the good, the bad, and the ugly. Annual Review of Physiology, 65, 45–79.PubMed

Bagga, S., Bracht, J., Hunter, S., Massirer, K., Holtz, J., Eachus, R., et al. (2005). Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell, 122(4), 553–563.PubMed

Olsen, P. H., & Ambros, V. (1999). The lin-4 regulatory RNA controls developmental timing in Caenorhabditis elegans by blocking LIN-14 protein synthesis after the initiation of translation. Developmental Biology, 216(2), 671–680.PubMed

Guo, H., Ingolia, N. T., Weissman, J. S., & Bartel, D. P. (2010). Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature, 466(7308), 835–840.PubMedPubMedCentral

Bronze-da-Rocha, E. (2014, 2014). MicroRNAs expression profiles in cardiovascular diseases. Biomed Res Int, 985408.

Chen, L. J., Xu, R., Yu, H. M., Chang, Q., & Zhong, J. C. (2015). The ACE2/Apelin signaling, microRNAs, and hypertension. International Journal of Hypertension, 2015, 896861.PubMedPubMedCentral

Pang, K. C., Frith, M. C., & Mattick, J. S. (2006). Rapid evolution of noncoding RNAs: lack of conservation does not mean lack of function. Trends in Genetics, 22(1), 1–5.PubMed

10.

Devaux, Y., Zangrando, J., Schroen, B., Creemers, E. E., Pedrazzini, T., Chang, C. P., et al. (2015). Long noncoding RNAs in cardiac development and ageing. Nature Reviews. Cardiology, 12(7), 415–425.PubMed

11.

Hansen, T. B., Jensen, T. I., Clausen, B. H., Bramsen, J. B., Finsen, B., Damgaard, C. K., et al. (2013). Natural RNA circles function as efficient microRNA sponges. Nature, 495(7441), 384–388.PubMed

12.

Lasda, E., & Parker, R. (2014). Circular RNAs: diversity of form and function. RNA, 20(12), 1829–1842.PubMedPubMedCentral

13.

Jeck, W. R., Sorrentino, J. A., Wang, K., Slevin, M. K., Burd, C. E., Liu, J., et al. (2013). Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA, 19(2), 141–157.PubMedPubMedCentral

14.

Zhang, X. O., Wang, H. B., Zhang, Y., Lu, X., Chen, L. L., & Yang, L. (2014). Complementary sequence-mediated exon circularization. Cell, 159(1), 134–147.PubMed

15.

Ashwal-Fluss, R., Meyer, M., Pamudurti, N. R., Ivanov, A., Bartok, O., Hanan, M., et al. (2014). circRNA biogenesis competes with pre-mRNA splicing. Molecular Cell, 56(1), 55–66.PubMed

16.

Zhang, Y., Zhang, X. O., Chen, T., Xiang, J. F., Yin, Q. F., Xing, Y. H., et al. (2013). Circular intronic long noncoding RNAs. Molecular Cell, 51(6), 792–806.PubMed

17.

Memczak, S., Jens, M., Elefsinioti, A., Torti, F., Krueger, J., Rybak, A., et al. (2013). Circular RNAs are a large class of animal RNAs with regulatory potency. Nature, 495(7441), 333–338.

18.

Kapusta, A., & Feschotte, C. (2014). Volatile evolution of long noncoding RNA repertoires: mechanisms and biological implications. Trends in Genetics, 30(10), 439–452.PubMed

19.

Ounzain, S., Micheletti, R., Beckmann, T., Schroen, B., Alexanian, M., Pezzuto, I., et al. (2015). Genome-wide profiling of the cardiac transcriptome after myocardial infarction identifies novel heart-specific long non-coding RNAs. European Heart Journal, 36(6), 353–368a.PubMed

20.

Zhao, Y., Li, H., Fang, S., Kang, Y., Wu, W., Hao, Y., et al. (2016). NONCODE 2016: an informative and valuable data source of long non-coding RNAs. Nucleic Acids Research, 44(D1), D203–D208.PubMed

21.

Sun, L., Zhang, Y., Zhang, Y., Gu, Y., Xuan, L., Liu, S., et al. (2014). Expression profile of long non-coding RNAs in a mouse model of cardiac hypertrophy. International Journal of Cardiology, 177(1), 73–75.PubMed

22.

Li, X., Zhang, L., & Liang, J. (2016). Unraveling the expression profiles of long noncoding RNAs in rat cardiac hypertrophy and functions of lncRNA BC088254 in cardiac hypertrophy induced by transverse aortic constriction. Cardiology, 134(2), 84–98.PubMed

23.

Yang, K. C., Yamada, K. A., Patel, A. Y., Topkara, V. K., George, I., Cheema, F. H., et al. (2014). Deep RNA sequencing reveals dynamic regulation of myocardial noncoding RNAs in failing human heart and remodeling with mechanical circulatory support. Circulation, 129(9), 1009–1021.PubMedPubMedCentral

24.

Schiano, C., Costa, V., Aprile, M., Grimaldi, V., Maiello, C., Esposito, R., et al. (2017). Heart failure: pilot transcriptomic analysis of cardiac tissue by RNA-sequencing. Cardiol J.

25.

Zhang, J., Feng, C., Song, C., Ai, B., Bai, X., Liu, Y., et al. (2018). Identification and analysis of a key long non-coding RNAs (lncRNAs)-associated module reveal functional lncRNAs in cardiac hypertrophy. Journal of Cellular and Molecular Medicine, 22(2), 892–903.PubMed

26.

Wang, K., Liu, F., Zhou, L. Y., Long, B., Yuan, S. M., Wang, Y., et al. (2014). The long noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489. Circulation Research, 114(9), 1377–1388.PubMed

27.

Zhu, X. H., Yuan, Y. X., Rao, S. L., & Wang, P. (2016). LncRNA MIAT enhances cardiac hypertrophy partly through sponging miR-150. European Review for Medical and Pharmacological Sciences, 20(17), 3653–3660.PubMed

28.

Lai, Y. J., He, S., Ma, L. M., Lin, H., Ren, B. Y., Ma, J., et al. (2017). HOTAIR functions as a competing endogenous RNA to regulate PTEN expression by inhibiting miR-19 in cardiac hypertrophy. Molecular and Cellular Biochemistry, 432(1–2), 179–187.PubMed

29.

Jiang, F., Zhou, X., & Huang, J. (2016). Long non-coding RNA-ROR mediates the reprogramming in cardiac hypertrophy. PLoS One, 11(4), e0152767.PubMedPubMedCentral

30.

Keniry, A., Oxley, D., Monnier, P., Kyba, M., Dandolo, L., Smits, G., et al. (2012). The H19 lincRNA is a developmental reservoir of miR-675 that suppresses growth and lgf1r. Nature Cell Biology, 14(7), 659–665.PubMedPubMedCentral

31.

Liu, L. T., An, X. B., Li, Z. H., Song, Y., Li, L. L., Zuo, S., et al. (2016). The H19 long noncoding RNA is a novel negative regulator of cardiomyocyte hypertrophy. Cardiovascular Research, 111(1), 56–65.PubMed

32.

Han, P., Li, W., Lin, C. H., Yang, J., Shang, C., Nuernberg, S. T., et al. (2014). A long noncoding RNA protects the heart from pathological hypertrophy. Nature, 514(7520), 102–106.PubMedPubMedCentral

33.

Wang, Z., Zhang, X. J., Ji, Y. X., Zhang, P., Deng, K. Q., Gong, J., et al. (2016). The long noncoding RNA Chaer defines an epigenetic checkpoint in cardiac hypertrophy. Nature Medicine, 22(10), 1131–1139.PubMedPubMedCentral

34.

Shao, M., Chen, G., Lv, F., Liu, Y., Tian, H., Tao, R., et al. (2017). LncRNA TINCR attenuates cardiac hypertrophy by epigenetically silencing CaMKII. Oncotarget, 8(29), 47565–47573.PubMedPubMedCentral

35.

Viereck, J., Kumarswamy, R., Foinquinos, A., Xiao, K., Avramopoulos, P., Kunz, M., et al. (2016). Long noncoding RNA Chast promotes cardiac remodeling. Science Translational Medicine, 8(326), 326ra322.

36.

Sun, W., Julie Li, Y. S., Huang, H. D., Shyy, J. Y., & Chien, S. (2010). MicroRNA: a master regulator of cellular processes for bioengineering systems. Annual Review of Biomedical Engineering, 12, 1–27.PubMed

37.

Zhao, Y., Ransom, J. F., Li, A., Vedantham, V., von Drehle, M., Muth, A. N., et al. (2007). Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell, 129(2), 303–317.PubMed

38.

Zhao, Y., Samal, E., & Srivastava, D. (2005). Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature, 436(7048), 214–220.PubMed

39.

Chen, J. F., Mandel, E. M., Thomson, J. M., Wu, Q., Callis, T. E., Hammond, S. M., et al. (2006). The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nature Genetics, 38(2), 228–233.PubMed

40.

Yang, B., Lin, H., Xiao, J., Lu, Y., Luo, X., Li, B., et al. (2007). The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nature Medicine, 13(4), 486–491.PubMed

41.

Sayed, D., Hong, C., Chen, I. Y., Lypowy, J., & Abdellatif, M. (2007). MicroRNAs play an essential role in the development of cardiac hypertrophy. Circulation Research, 100(3), 416–424.PubMed

42.

Ikeda, S., He, A., Kong, S. W., Lu, J., Bejar, R., Bodyak, N., et al. (2009). MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Molecular and Cellular Biology, 29(8), 2193–2204.PubMedPubMedCentral

43.

Elia, L., Contu, R., Quintavalle, M., Varrone, F., Chimenti, C., Russo, M. A., et al. (2009). Reciprocal regulation of microRNA-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions. Circulation, 120(23), 2377–2385.PubMedPubMedCentral

44.

Li, Q., Song, X. W., Zou, J., Wang, G. K., Kremneva, E., Li, X. Q., et al. (2010). Attenuation of microRNA-1 derepresses the cytoskeleton regulatory protein twinfilin-1 to provoke cardiac hypertrophy. Journal of Cell Science, 123(Pt 14), 2444–2452.PubMed

45.

Yuan, W., Tang, C., Zhu, W., Zhu, J., Lin, Q., Fu, Y., et al. (2016). CDK6 mediates the effect of attenuation of miR-1 on provoking cardiomyocyte hypertrophy. Molecular and Cellular Biochemistry, 412(1–2), 289–296.PubMed

46.

Karakikes, I., Chaanine, A. H., Kang, S., Mukete, B. N., Jeong, D., Zhang, S., et al. (2013). Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. Journal of the American Heart Association, 2(2), e000078.PubMedPubMedCentral

47.

Liu, N., Williams, A. H., Kim, Y., McAnally, J., Bezprozvannaya, S., Sutherland, L. B., et al. (2007). An intragenic MEF2-dependent enhancer directs muscle-specific expression of microRNAs 1 and 133. Proceedings of the National Academy of Sciences of the United States of America, 104(52), 20844–20849.PubMedPubMedCentral

48.

McCarthy, J. J. (2008). MicroRNA-206: the skeletal muscle-specific myomiR. Biochimica et Biophysica Acta, 1779(11), 682–691.PubMedPubMedCentral

49.

Care, A., Catalucci, D., Felicetti, F., Bonci, D., Addario, A., Gallo, P., et al. (2007). MicroRNA-133 controls cardiac hypertrophy. Nature Medicine, 13(5), 613–618.PubMed

50.

Liu, N., Bezprozvannaya, S., Williams, A. H., Qi, X., Richardson, J. A., Bassel-Duby, R., et al. (2008). microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes & Development, 22(23), 3242–3254.

51.

Luo, X., Lin, H., Pan, Z., Xiao, J., Zhang, Y., Lu, Y., et al. (2008). Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart. The Journal of Biological Chemistry, 283(29), 20045–20052.PubMed

52.

Dong, D. L., Chen, C., Huo, R., Wang, N., Li, Z., Tu, Y. J., et al. (2010). Reciprocal repression between microRNA-133 and calcineurin regulates cardiac hypertrophy: a novel mechanism for progressive cardiac hypertrophy. Hypertension, 55(4), 946–952.PubMed

53.

Li, Q., Lin, X., Yang, X., & Chang, J. (2010). NFATc4 is negatively regulated in miR-133a-mediated cardiomyocyte hypertrophic repression. American Journal of Physiology. Heart and Circulatory Physiology, 298(5), H1340–H1347.PubMedPubMedCentral

54.

Han, M., Yang, Z., Sayed, D., He, M., Gao, S., Lin, L., et al. (2012). GATA4 expression is primarily regulated via a miR-26b-dependent post-transcriptional mechanism during cardiac hypertrophy. Cardiovascular Research, 93(4), 645–654.PubMedPubMedCentral

55.

Li, R., Yan, G., Zhang, Q., Jiang, Y., Sun, H., Hu, Y., et al. (2013). miR-145 inhibits isoproterenol-induced cardiomyocyte hypertrophy by targeting the expression and localization of GATA6. FEBS Letters, 587(12), 1754–1761.PubMedPubMedCentral

56.

Ganesan, J., Ramanujam, D., Sassi, Y., Ahles, A., Jentzsch, C., Werfel, S., et al. (2013). MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors. Circulation, 127(21), 2097–2106.PubMed

57.

Wang, Y. S., Zhou, J., Hong, K., Cheng, X. S., & Li, Y. G. (2015). MicroRNA-223 displays a protective role against cardiomyocyte hypertrophy by targeting cardiac troponin I-interacting kinase. Cellular Physiology and Biochemistry, 35(4), 1546–1556.PubMed

58.

Lee, J. S., Yang, D. K., Park, J. H., Kim, J. O., Park, W. J., Cho, C., et al. (2017). MicroRNA-101b attenuates cardiomyocyte hypertrophy by inhibiting protein kinase C epsilon signaling. FEBS Letters, 591(1), 16–27.PubMed

59.

Duan, Q., Chen, C., Yang, L., Li, N., Gong, W., Li, S., et al. (2015). MicroRNA regulation of unfolded protein response transcription factor XBP1 in the progression of cardiac hypertrophy and heart failure in vivo. Journal of Translational Medicine, 13, 363.PubMedPubMedCentral

60.

Yang, Y., Ago, T., Zhai, P., Abdellatif, M., & Sadoshima, J. (2011). Thioredoxin 1 negatively regulates angiotensin II-induced cardiac hypertrophy through upregulation of miR-98/let-7. Circulation Research, 108(3), 305–313.PubMed

61.

Huang, J., Sun, W., Huang, H., Ye, J., Pan, W., Zhong, Y., et al. (2014). miR-34a modulates angiotensin II-induced myocardial hypertrophy by direct inhibition of ATG9A expression and autophagic activity. PLoS One, 9(4), e94382.PubMedPubMedCentral

62.

Pan, W., Zhong, Y., Cheng, C., Liu, B., Wang, L., Li, A., et al. (2013). MiR-30-regulated autophagy mediates angiotensin II-induced myocardial hypertrophy. PLoS One, 8(1), e53950.PubMedPubMedCentral

63.

Yan, M., Chen, C., Gong, W., Yin, Z., Zhou, L., Chaugai, S., et al. (2015). miR-21-3p regulates cardiac hypertrophic response by targeting histone deacetylase-8. Cardiovascular Research, 105(3), 340–352.PubMed

64.

Wang, K., Long, B., Zhou, J., & Li, P. F. (2010). miR-9 and NFATc3 regulate myocardin in cardiac hypertrophy. The Journal of Biological Chemistry, 285(16), 11903–11912.PubMedPubMedCentral

65.

Kim, J. O., Song, D. W., Kwon, E. J., Hong, S. E., Song, H. K., Min, C. K., et al. (2015). miR-185 plays an anti-hypertrophic role in the heart via multiple targets in the calcium-signaling pathways. PLoS One, 10(3), e0122509.PubMedPubMedCentral

66.

van Rooij, E., Sutherland, L. B., Liu, N., Williams, A. H., McAnally, J., Gerard, R. D., et al. (2006). A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proceedings of the National Academy of Sciences of the United States of America, 103(48), 18255–18260.PubMedPubMedCentral

67.

Zhang, X., Ji, R., Liao, X., Castillero, E., Kennel, P. J., Brunjes, D. L., et al. (2018). miR-195 regulates metabolism in failing myocardium via alterations in SIRT3 expression and mitochondrial protein acetylation. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.117.030486.

68.

Callis, T. E., Pandya, K., Seok, H. Y., Tang, R. H., Tatsuguchi, M., Huang, Z. P., et al. (2009). MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. The Journal of Clinical Investigation, 119(9), 2772–2786.PubMedPubMedCentral

69.

Bernardo, B. C., Gao, X. M., Winbanks, C. E., Boey, E. J., Tham, Y. K., Kiriazis, H., et al. (2012). Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. Proceedings of the National Academy of Sciences of the United States of America, 109(43), 17615–17620.PubMedPubMedCentral

70.

Bang, C., Batkai, S., Dangwal, S., Gupta, S. K., Foinquinos, A., Holzmann, A., et al. (2014). Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. The Journal of Clinical Investigation, 124(5), 2136–2146.PubMedPubMedCentral

71.

da Costa Martins, P. A., Salic, K., Gladka, M. M., Armand, A. S., Leptidis, S., el Azzouzi, H., et al. (2010). MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. Nature Cell Biology, 12(12), 1220–1227.PubMed

72.

Wang, J., Song, Y., Zhang, Y., Xiao, H., Sun, Q., Hou, N., et al. (2012). Cardiomyocyte overexpression of miR-27b induces cardiac hypertrophy and dysfunction in mice. Cell Research, 22(3), 516–527.PubMed

73.

Wang, K., Lin, Z. Q., Long, B., Li, J. H., Zhou, J., & Li, P. F. (2012). Cardiac hypertrophy is positively regulated by microRNA miR-23a. The Journal of Biological Chemistry, 287(1), 589–599.PubMed

74.

Yang, J., Nie, Y., Wang, F., Hou, J., Cong, X., Hu, S., et al. (2013). Reciprocal regulation of miR-23a and lysophosphatidic acid receptor signaling in cardiomyocyte hypertrophy. Biochimica et Biophysica Acta, 1831(8), 1386–1394.PubMed

75.

Ucar, A., Gupta, S. K., Fiedler, J., Erikci, E., Kardasinski, M., Batkai, S., et al. (2012). The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nature Communications, 3, 1078.PubMedPubMedCentral

76.

Wang, C., Wang, S., Zhao, P., Wang, X., Wang, J., Wang, Y., et al. (2012). MiR-221 promotes cardiac hypertrophy in vitro through the modulation of p27 expression. Journal of Cellular Biochemistry, 113(6), 2040–2046.PubMed

77.

Ge, Y., Pan, S., Guan, D., Yin, H., Fan, Y., Liu, J., et al. (2013). MicroRNA-350 induces pathological heart hypertrophy by repressing both p38 and JNK pathways. Biochimica et Biophysica Acta, 1832(1), 1–10.PubMed

78.

Huang, Z. P., Chen, J., Seok, H. Y., Zhang, Z., Kataoka, M., Hu, X., et al. (2013). MicroRNA-22 regulates cardiac hypertrophy and remodeling in response to stress. Circulation Research, 112(9), 1234–1243.PubMedPubMedCentral

79.

Li, C., Li, X., Gao, X., Zhang, R., Zhang, Y., Liang, H., et al. (2014). MicroRNA-328 as a regulator of cardiac hypertrophy. International Journal of Cardiology, 173(2), 268–276.PubMed

80.

He, W., Huang, H., Xie, Q., Wang, Z., Fan, Y., Kong, B., et al. (2016). MiR-155 knockout in fibroblasts improves cardiac remodeling by targeting tumor protein p53-inducible nuclear protein 1. Journal of Cardiovascular Pharmacology and Therapeutics, 21(4), 423–435.PubMed

81.

Sanger, H. L., Klotz, G., Riesner, D., Gross, H. J., & Kleinschmidt, A. K. (1976). Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. Proceedings of the National Academy of Sciences of the United States of America, 73(11), 3852–3856.PubMedPubMedCentral

82.

Szabo, L., & Salzman, J. (2016). Detecting circular RNAs: bioinformatic and experimental challenges. Nature Reviews. Genetics, 17(11), 679–692.PubMedPubMedCentral

83.

Qu, S., Zhong, Y., Shang, R., Zhang, X., Song, W., Kjems, J., et al. (2016). The emerging landscape of circular RNA in life processes. RNA Biol, 1–8.

84.

Zheng, Q., Bao, C., Guo, W., Li, S., Chen, J., Chen, B., et al. (2016). Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs. Nature Communications, 7, 11215.PubMedPubMedCentral

85.

Wang, K., Long, B., Liu, F., Wang, J. X., Liu, C. Y., Zhao, B., et al. (2016). A circular RNA protects the heart from pathological hypertrophy and heart failure by targeting miR-223. European Heart Journal, 37(33), 2602–2611.PubMed

86.

Jakobi, T., Czaja-Hasse, L. F., Reinhardt, R., & Dieterich, C. (2016). Profiling and validation of the circular RNA repertoire in adult murine hearts. Genomics, Proteomics & Bioinformatics, 14(4), 216–223.

87.

Khan, M. A., Reckman, Y. J., Aufiero, S., van den Hoogenhof, M. M., van der Made, I., Beqqali, A., et al. (2016). RBM20 regulates circular RNA production from the Titin gene. Circulation Research, 119(9), 996–1003.PubMed

88.

Werfel, S., Nothjunge, S., Schwarzmayr, T., Strom, T. M., Meitinger, T., & Engelhardt, S. (2016). Characterization of circular RNAs in human, mouse and rat hearts. Journal of Molecular and Cellular Cardiology, 98, 103–107.PubMed

89.

Tan, W. L., Lim, B. T., Anene-Nzelu, C. G., Ackers-Johnson, M., Dashi, A., See, K., et al. (2017). A landscape of circular RNA expression in the human heart. Cardiovascular Research, 113(3), 298–309.PubMed

90.

Fernandes, T., Hashimoto, N. Y., Magalhaes, F. C., Fernandes, F. B., Casarini, D. E., Carmona, A. K., et al. (2011). Aerobic exercise training-induced left ventricular hypertrophy involves regulatory microRNAs, decreased angiotensin-converting enzyme-angiotensin II, and synergistic regulation of angiotensin-converting enzyme 2-angiotensin (1-7). Hypertension, 58(2), 182–189.PubMedPubMedCentral

91.

Ramasamy, S., Velmurugan, G., Shanmugha Rajan, K., Ramprasath, T., & Kalpana, K. (2015). MiRNAs with apoptosis regulating potential are differentially expressed in chronic exercise-induced physiologically hypertrophied hearts. PLoS One, 10(3), e0121401.PubMedPubMedCentral

92.

Ma, Z., Qi, J., Meng, S., Wen, B., & Zhang, J. (2013). Swimming exercise training-induced left ventricular hypertrophy involves microRNAs and synergistic regulation of the PI3K/AKT/mTOR signaling pathway. European Journal of Applied Physiology, 113(10), 2473–2486.PubMed

93.

Soci, U. P., Fernandes, T., Hashimoto, N. Y., Mota, G. F., Amadeu, M. A., Rosa, K. T., et al. (2011). MicroRNAs 29 are involved in the improvement of ventricular compliance promoted by aerobic exercise training in rats. Physiological Genomics, 43(11), 665–673.PubMedPubMedCentral

94.

Martinelli, N. C., Cohen, C. R., Santos, K. G., Castro, M. A., Biolo, A., Frick, L., et al. (2014). An analysis of the global expression of microRNAs in an experimental model of physiological left ventricular hypertrophy. PLoS One, 9(4), e93271.PubMedPubMedCentral

95.

Liu, X., Xiao, J., Zhu, H., Wei, X., Platt, C., Damilano, F., et al. (2015). miR-222 is necessary for exercise-induced cardiac growth and protects against pathological cardiac remodeling. Cell Metabolism, 21(4), 584–595.PubMedPubMedCentral

96.

Shi, J., Bei, Y., Kong, X., Liu, X., Lei, Z., Xu, T., et al. (2017). miR-17-3p contributes to exercise-induced cardiac growth and protects against myocardial ischemia-reperfusion injury. Theranostics, 7(3), 664–676.PubMedPubMedCentral

97.

Li, Z., Liu, L., Hou, N., Song, Y., An, X., Zhang, Y., et al. (2016). miR-199-sponge transgenic mice develop physiological cardiac hypertrophy. Cardiovascular Research, 110(2), 258–267.PubMed

98.

Yang, L., Li, Y., Wang, X., Mu, X., Qin, D., Huang, W., et al. (2016). Overexpression of miR-223 tips the balance of pro- and anti-hypertrophic signaling cascades toward physiologic cardiac hypertrophy. The Journal of Biological Chemistry, 291(30), 15700–15713.PubMedPubMedCentral

Titel: Noncoding RNAs in Cardiac Hypertrophy
verfasst von: Yongqin Li
Yajun Liang
Yujiao Zhu
Yuhui Zhang
Yihua Bei
Publikationsdatum: 31.08.2018
Verlag: Springer US
Erschienen in: Journal of Cardiovascular Translational Research / Ausgabe 6/2018
Print ISSN: 1937-5387
Elektronische ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-018-9797-x

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Noncoding RNAs in Cardiac Hypertrophy

Abstract

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

Update Kardiologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2018

A Simple Modified Framingham Scoring System to Predict Obstructive Coronary Artery Disease

Development of a Novel Human Cell-Derived Tissue-Engineered Heart Valve for Transcatheter Aortic Valve Replacement: an In Vitro and In Vivo Feasibility Study

Effect of Long-Term Exercise Training on lncRNAs Expression in the Vascular Injury of Insulin Resistance

Protein Profiling in Serum and Cerebrospinal Fluid Following Complex Surgery on the Thoracic Aorta Identifies Biological Markers of Neurologic Injury

Aerobic Exercise Prevents Insulin Resistance Through the Regulation of miR-492/Resistin Axis in Aortic Endothelium

Serum or Plasma Matrix Metalloproteinase (MMP)-9 Levels and Cardiovascular Diseases

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

Update Kardiologie